Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders

References

• Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6):1470–9.
   PubMed Web of Science ®Google Scholar
• Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(5 Suppl 46): S4–11.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Nadler S. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev. 2013;12(7):758–67.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63(10):2854–64.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kremer JM, Russell A, Box J, Abud-Mendoza C, Elizondo MG, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. 2012;71(6):857–61.
   PubMed Web of Science ®Google Scholar
• Nash P, Nayiager S, Genovese MC, Kivitz AJ, Oelke K, Ludivico C, et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013;65(5):718–28.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28–38.
   PubMed Web of Science ®Google Scholar
• Schiff M, Weinblatt ME, Valente R, van der HD, Citera G, Elegbe A, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2013;73:86–94.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Ishiguro N, Inokuma S, Ryu J, Takei S, et al. Safety and effectiveness of abatacept in 3985 Japanese patients with rheumatoid arthritis; Japan all-cases post-marketing surveillance. Arthritis Rheum. 2013;65(Suppl 10):1415.
   Google Scholar
• Matsubara T, Inoue H, Iwahashi M, Yamazaki A, Takeuchi T, Japan Abatacept Study Group. A multi-center, double-dummy, double-blind study of subcutaneous (SC) abatacept (ABA) compared with intravenous (IV) ABA in Japanese rheumatoid arthritis patients with inadequate response to methotrexate [abstract]. Ann Rheum Dis. 2012;71(Supp l3):197.
   Google Scholar
• Matsubara T, Yamana S, Tohma S, Takeuchi T, Kondo H, Kohsaka H, et al. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. Mod Rheumatol. 2013; 23(4):634–45.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjo S, et al. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol. 2013;23(2):226–35.
   PubMed Web of Science ®Google Scholar
• Iwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, et al. Efficacy, safety, pharmacokinetics, and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. Mod Rheumatol. 2014;24:885–91.
   PubMed Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925–6.
   PubMed Web of Science ®Google Scholar
• ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. J Postgrad Med. 2001;47:199–203.
   PubMedGoogle Scholar
• Evaluation and Licensing Division Pharmaceutical and Food Safety Bureau Ministry of Health Labour and Welfare. Guideline for Clinical Evaluation of Anti-rheumatic Drugs. Available from: http://www.pref.chiba.lg.jp/yakumu/iyakubugaihin/documents/rgg.pdf (accessed 27 November 2014).
   Google Scholar
• Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis. 2012;71(1):38–44.
   PubMed Web of Science ®Google Scholar
• Humira Summary of Product Characteristics. Available from: http://www.medicines.org.uk/EMC/medicine/21201/SPC/Humira+ Pre-filled+ Pen%2c+ Pre-filled+ Syringe+ and+ Vial/ (accessed 27 November 2014).
   Google Scholar
• Frenken LA, van Lier HJ, Gerlag PG, den HM, Koene RA. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. BMJ. 1991;303(6797):288.
   PubMed Web of Science ®Google Scholar
• Alten R, Kaine J, Keystone EC, Nash P, Delaet I, Qi K, et al. Safety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): Integrated analysis of five clinical trials up to 4.5 years. Ann Rheum Dis. 2011;70 (Suppl 3):617.
   Google Scholar
• Alten R, Kaine J, Keystone EC, Nash P, Delaet I, Qi K, Genovese M. Safety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure. Arthritis Rheum. 2011;63 (Suppl 10):S150–1.
   Web of Science ®Google Scholar
• Schellekens H. The immunogenicity of therapeutic proteins. Discov Med. 2010;9(49):560–4.
   PubMedGoogle Scholar